Neoandrographolide是一种从穿心莲中分离的二萜类化合物，具有抗炎和降脂的作用。
Cas No.:27215-14-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata, which exhibits anti‑inflammatory and lipid‑lowering effects[1-2]. Neoandrographolide is applicable for research on antiviral, antitumor, cardiovascular and cerebrovascular diseases, osteoporosis, and type 2 diabetes[3-4].
In vitro, co‑treatment of RAW 264.7 macrophages with Neoandrographolide (30–150μM) and LPS (5μg/ml) for 24–36h. Neoandrographolide significantly inhibited the production of TNF‑α and nitric oxide (NO)[5]. pretreatment of bone marrow‑derived mouse macrophages with Neoandrographolide (1.5–90μM) for 2h, followed by stimulation with LPS (5μg/ml) for 24h. Neoandrographolide markedly suppressed the expression of iNOS and COX‑2, and simultaneously reduced the generation of NO and PGE2[6].
In vivo, pretreatment of C57BL/6 mice with Neoandrographolide (10mg/kg/day) via intraperitoneal injection for 6 days prior to establishing a myocardial ischemia/reperfusion injury model. Neoandrographolide significantly improved cardiac systolic function, reduced myocardial infarct area and inflammatory cell infiltration, and inhibited cardiomyocyte apoptosis[7]. In an ovariectomy‑induced osteoporosis model, C57BL/6J mice were treated with Neoandrographolide (15mg/kg/day and 30mg/kg/day) by intraperitoneal injection for 8 weeks. Neoandrographolide significantly alleviated bone loss and improved trabecular microstructural parameters[8].
References:
[1] Ghosh N, Ghosh R, Mandal V, et al. Recent advances in herbal medicine for treatment of liver diseases. Pharm Biol. 2011 Sep;49(9):970-88.
[2] Yang T, Shi HX, Wang ZT, et al. Hypolipidemic effects of andrographolide and neoandrographolide in mice and rats. Phytother Res. 2013 Apr;27(4):618-23.
[3] Sangeetha K, Martín-Acebes MA, Saiz JC, et al. Molecular docking and antiviral activities of plant derived compounds against zika virus. Microb Pathog. 2020 Dec;149:104540.
[4] Jadhav AK, Karuppayil SM. Andrographis paniculata (Burm. F) Wall ex Nees: Antiviral properties. Phytother Res. 2021 Oct;35(10):5365-5373.
[5] Liu J, Wang ZT, Ji LL. In vivo and in vitro anti-inflammatory activities of neoandrographolide. Am J Chin Med. 2007;35(2):317-28.
[6] Liu J, Wang ZT, Ji LL, et al. Inhibitory effects of neoandrographolide on nitric oxide and prostaglandin E2 production in LPS-stimulated murine macrophage. Mol Cell Biochem. 2007 Apr;298(1-2):49-57.
[7] Liu Y, Liu Y, Zhang HL, et al. Amelioratory effect of neoandrographolide on myocardial ischemic-reperfusion injury by its anti-inflammatory and anti-apoptotic activities. Environ Toxicol. 2021 Dec;36(12):2367-2379.
[8] Tang K, Deng W, Huang Z, et al. Neoandrographolide inhibits mature osteoclast differentiation to alleviate bone loss and treat osteoporosis. Front Pharmacol. 2025 Feb 11;16:1466057.
Neoandrographolide是一种从穿心莲中分离的二萜类化合物，具有抗炎和降脂的作用[1-2]。Neoandrographolide可用于抗病毒、抗肿瘤、心脑血管疾病、骨质疏松症和2型糖尿病等相关研究[3-4]。
在体外，Neoandrographolide（30–150μM）与LPS（5μg/ml）共同处理RAW 264.7巨噬细胞24–36小时，显著抑制TNF-α和一氧化氮（NO）的产生[5]。Neoandrographolide（1.5–90μM）预处理骨髓来源的小鼠巨噬细胞2小时，随后以LPS（5μg/ml）刺激24小时，显著抑制iNOS和COX-2的表达，同时降低NO和PGE2的产生[6]。
在体内，Neoandrographolide（10mg/kg/day）通过腹腔注射预处理C57BL/6小鼠6天，随后建立心肌缺血/再灌注损伤模型。Neoandrographolide显著改善了心脏收缩功能、减少了心肌梗死面积和炎症细胞浸润，同时抑制了心肌细胞凋亡[7]。Neoandrographolide（15mg/kg/day和30mg/kg/day）通过腹腔注射给药，用于处理经双侧卵巢切除术建立的C57BL/6J小鼠骨质疏松模型8周。Neoandrographolide显著减轻了骨量丢失，并改善了骨小梁微观结构参数[8]。
| Cell experiment [1]: | |
Cell lines | RAW 264.7 cells (mouse monocyte-macrophage cell line) |
Preparation Method | RAW 264.7 cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin at 37°C in 5% CO₂. For respiratory burst assays, cells were adjusted to 2×10⁵ cells/mL and stimulated with phorbol-12-myristate-13-acetate (PMA; 125ng/mL). For nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) production assays, cells were adjusted to 1 × 10⁶ cells/mL and stimulated with lipopolysaccharide (LPS; 5 μg/mL). Neoandrographolide (1.5–150μM) was co-administered with the stimulators. |
Reaction Conditions | 1.5–150μM; 24-36h. |
Applications | Neoandrographolide dose-dependently suppressed PMA-stimulated respiratory bursts in RAW 264.7 macrophages at concentrations from 7.5 to 150μM. Neoandrographolide also inhibited LPS-induced production of NO and TNF-α in a dose-dependent manner (30–150μM). No cytotoxicity was observed at concentrations up to 90μM. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | Mice were subjected to myocardial ischemia/reperfusion (MI/R) injury by 30 minutes of left anterior descending coronary artery (LAD) ligation followed by reperfusion. They were randomly divided into Sham, MI/R, and MI/R + Neoandrographolide groups. Neo was administered intraperitoneally for 6 consecutive days before the surgical procedure. |
Dosage form | 10mg/kg/day; i.p.; 6 days. |
Applications | Neoandrographolide pretreatment significantly improved heart systolic function, reduced myocardial infarct size, attenuated inflammatory cell infiltration, and decreased cardiomyocyte apoptosis in mice with MI/R. These cardioprotective effects were associated with the inhibition of the NF-κB signaling pathway and modulation of the Bax/Bcl-2 apoptotic pathway. |
References: | |
| Cas No. | 27215-14-1 | SDF | |
| 别名 | 新穿心莲内酯; Neoandrographiside | ||
| Canonical SMILES | C[C@@]([C@@H]1CCC2=CCOC2=O)(CCC3)[C@@](CCC1=C)([H])[C@]3(C)CO[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO | ||
| 分子式 | C26H40O8 | 分子量 | 480.59 |
| 溶解度 | DMSO: ≥ 250 mg/mL (520.19 mM) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0808 mL | 10.4039 mL | 20.8078 mL |
| 5 mM | 416.2 μL | 2.0808 mL | 4.1616 mL |
| 10 mM | 208.1 μL | 1.0404 mL | 2.0808 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet